Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Neoplasms of Male Genital Organs
Conditions
Malignant Neoplasms of Male Genital Organs
Trial Timeline
Jun 1, 2016 → May 10, 2020
NCT ID
NCT02740127About Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol
Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol is a phase 3 stage product being developed by Merck for Malignant Neoplasms of Male Genital Organs. The current trial status is completed. This product is registered under clinical trial identifier NCT02740127. Target conditions include Malignant Neoplasms of Male Genital Organs.
What happened to similar drugs?
5 of 20 similar drugs in Malignant Neoplasms of Male Genital Organs were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02740127 | Phase 3 | Completed |
Competing Products
20 competing products in Malignant Neoplasms of Male Genital Organs